Weight loss medications can be effective tools for managing obesity when used alongside lifestyle changes, but they carry potential side effects that vary by drug type and individual factors. Understanding these effects—from common gastrointestinal symptoms to rare but serious complications—is essential for safe use. This guide examines the side effects of NHS-approved weight loss pills including orlistat, semaglutide (Wegovy), and liraglutide (Saxenda), explains how different medications affect your body, and provides practical advice on managing adverse effects. Whether you're considering treatment or currently taking weight loss medication, knowing what to expect and when to seek help ensures informed decision-making.

Common Side Effects of Weight Loss Pills

Weight loss medications, whether prescribed or obtained from a pharmacy, can produce a range of side effects that vary depending on the specific drug and individual patient factors. Understanding these effects is essential for making informed decisions about treatment.

Gastrointestinal symptoms represent the most frequently reported side effects across most weight loss medications. These include nausea, diarrhoea, constipation, abdominal pain, and flatulence. Medications that work by reducing fat absorption, such as orlistat, commonly cause oily stools, faecal urgency, and increased bowel movements. These effects occur because unabsorbed dietary fat passes through the digestive system. Patients often find these symptoms improve when they follow a lower-fat diet (typically less than 30% of daily calories from fat, or approximately 15 grams of fat per meal).

Orlistat is available in two strengths in the UK: prescription-strength Xenical (120 mg) and lower-dose Alli (60 mg), which is available from pharmacies without prescription for adults with a BMI of 28 kg/m² or above. Orlistat may reduce absorption of fat-soluble vitamins (A, D, E, K), so patients are advised to take a multivitamin supplement at bedtime or at least two hours after orlistat. If you take levothyroxine, separate it from orlistat by at least four hours. Patients taking warfarin should have their INR monitored more frequently, as reduced vitamin K absorption may affect clotting. Orlistat should not be taken with ciclosporin. Severe diarrhoea may reduce the effectiveness of oral contraceptives; use additional contraception if this occurs.

Central nervous system effects may occur with some medications, particularly those affecting appetite or neurotransmitter levels. Patients may experience headaches, dizziness, insomnia, or changes in mood. Some individuals report feeling anxious or experiencing a dry mouth. These symptoms tend to be more pronounced during the initial weeks of treatment and may diminish as the body adjusts to the medication.

Cardiovascular symptoms such as increased heart rate or elevated blood pressure require regular monitoring, particularly in patients with pre-existing cardiovascular conditions. Other commonly reported effects include fatigue, changes in taste perception, and mild dehydration. Maintaining adequate fluid intake and following dosing instructions carefully can help minimise these effects. If side effects persist beyond the first few weeks or significantly impact daily functioning, patients should consult their GP or prescribing clinician for review.

Important safety advice: Only obtain weight loss medicines from registered UK pharmacies or NHS services. The MHRA has warned about counterfeit and unlicensed products sold online, particularly fake GLP-1 medicines, which may be unsafe. If you experience a suspected side effect, report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Serious Risks and When to Seek Medical Help

Whilst most side effects of weight loss medications are mild and manageable, certain serious adverse reactions require immediate medical attention. Recognising these warning signs can prevent potentially life-threatening complications.

Call 999 or go to A&E immediately if you experience chest pain, severe shortness of breath, signs of stroke (sudden weakness, speech difficulties, facial drooping), or severe allergic reactions including facial swelling, difficulty breathing, or widespread rash. These symptoms may indicate serious cardiovascular events or anaphylaxis requiring urgent intervention.

Contact your GP or NHS 111 promptly if you develop persistent vomiting or diarrhoea lasting more than 24 hours, as this can lead to dehydration and electrolyte imbalances, particularly with GLP-1 receptor agonist medications. Signs of liver problems—including yellowing of the skin or eyes (jaundice), dark urine, pale stools, or persistent upper abdominal pain—warrant immediate medical review. Some weight loss medications have been associated with hepatotoxicity, though this remains rare.

Mental health changes require careful monitoring and are particularly important for patients taking naltrexone-bupropion (Mysimba). If you experience severe mood changes, depression, suicidal thoughts, or unusual behavioural changes, contact your healthcare provider immediately. Certain weight loss medications can affect neurotransmitter levels, potentially triggering or worsening psychiatric conditions.

Other serious concerns include signs of pancreatitis (severe upper abdominal pain radiating to the back, often with nausea and vomiting). If you are taking a GLP-1 receptor agonist and develop these symptoms, stop the medication and seek urgent medical review. Kidney problems (reduced urination, swelling in legs or feet, persistent fatigue) or gallbladder issues (severe right upper abdominal pain, particularly after eating fatty foods) also require prompt assessment. Rapid weight loss itself can increase gallstone risk.

Patients with diabetes should monitor for signs of hypoglycaemia (low blood sugar), including shakiness, confusion, sweating, and rapid heartbeat, as weight loss medications may necessitate adjustment of diabetes medications. If you are unable to maintain adequate hydration due to persistent vomiting or diarrhoea, contact your GP or NHS 111 for advice.

How Different Types of Weight Loss Medications Affect Your Body

Weight loss medications work through various mechanisms, each producing distinct physiological effects and side effect profiles. Understanding these differences helps patients and clinicians select the most appropriate treatment.

Lipase inhibitors, such as orlistat (available as prescription-strength Xenical 120 mg or pharmacy-only Alli 60 mg), work by blocking pancreatic and gastric lipases—enzymes responsible for breaking down dietary fats. This prevents approximately 25–30% of ingested fat from being absorbed in the intestine. The unabsorbed fat is then excreted, leading to characteristic gastrointestinal side effects including oily spotting, flatulence with discharge, and faecal urgency. These effects are directly proportional to dietary fat intake. If a meal is missed or contains no fat, the dose should be omitted. Orlistat may reduce absorption of fat-soluble vitamins (A, D, E, K), so patients are advised to take a multivitamin supplement at bedtime or at least two hours after orlistat. Important interactions include warfarin (monitor INR more frequently), levothyroxine (separate by at least four hours), and ciclosporin (avoid concurrent use).

GLP-1 receptor agonists, including semaglutide (Wegovy) and liraglutide (Saxenda), mimic the action of glucagon-like peptide-1, a hormone that regulates appetite and glucose metabolism. These medications slow gastric emptying, increase feelings of fullness, and reduce appetite through central nervous system pathways. Common side effects include nausea, vomiting, diarrhoea, and constipation, typically most pronounced during dose escalation. Patients should be aware of the risk of dehydration, particularly with persistent gastrointestinal symptoms, which may lead to acute kidney injury. There is also a risk of pancreatitis and gallbladder disease; patients should seek urgent medical review if severe abdominal pain develops.

Animal studies have shown thyroid C-cell tumours in rodents treated with GLP-1 receptor agonists, though the relevance to humans is unknown. Patients should report any neck lump, hoarseness, or difficulty swallowing. In people with diabetes, there is a potential risk of diabetic retinopathy progression, and blood glucose should be monitored as other diabetes medications may need adjustment to prevent hypoglycaemia.

Pregnancy and breastfeeding: Wegovy is contraindicated in pregnancy. Women of childbearing potential should use effective contraception and stop semaglutide at least two months before a planned pregnancy. Saxenda should not be used during pregnancy. Breastfeeding is not recommended whilst taking these medications.

Combination medications such as naltrexone-bupropion (Mysimba) work on multiple pathways. Naltrexone, an opioid antagonist, combined with bupropion, an antidepressant affecting dopamine and noradrenaline, acts on the central nervous system to reduce appetite and food cravings. Side effects may include nausea, constipation, headache, dizziness, and insomnia. This combination is contraindicated in patients with uncontrolled hypertension, seizure disorders, current or recent opioid use or dependence, abrupt withdrawal from alcohol or benzodiazepines, or those taking monoamine oxidase inhibitors (MAOIs). There is an increased risk of seizures and neuropsychiatric effects including mood changes and suicidal ideation; patients should be monitored closely, particularly during the early weeks of treatment.

Each medication class requires individualised assessment of suitability based on patient medical history, concurrent medications, and risk factors.

Managing Side Effects While Taking Weight Loss Pills

Effective side effect management can significantly improve treatment adherence and outcomes. Most adverse effects can be minimised through practical strategies and lifestyle modifications.

Dietary adjustments are particularly important for medications like orlistat. Distributing fat intake evenly across three main meals, with no more than 15 grams of fat per meal, substantially reduces gastrointestinal symptoms. If a meal is missed or contains no fat, omit the orlistat dose. Keeping a food diary helps identify problematic foods. For medications causing nausea, eating smaller, more frequent meals and avoiding spicy, fatty, or strong-smelling foods can help. Taking medication with food (when recommended) or on an empty stomach (as directed) optimises absorption and may reduce stomach upset.

Timing and dosing strategies can minimise side effects. For medications causing insomnia or jitteriness, taking the dose earlier in the day prevents sleep disturbance. With GLP-1 receptor agonists, gradual dose escalation as prescribed allows the body to adjust, reducing nausea severity. Do not change or stop your treatment without medical advice; some medicines may require dose adjustments or tapering. Setting reminders ensures consistent timing, which helps maintain stable drug levels and reduces side effect fluctuations.

Hydration and supplementation are essential. Adequate fluid intake (approximately 2 litres daily) helps prevent constipation and supports kidney function. If you are unable to maintain hydration due to vomiting or diarrhoea, contact your GP or NHS 111 for advice. For medications affecting fat absorption, take a daily multivitamin containing fat-soluble vitamins at bedtime or at least two hours after orlistat to prevent nutritional deficiencies. If you take levothyroxine, separate it from orlistat by at least four hours. Patients experiencing dry mouth benefit from sugar-free gum or frequent water sips.

Communication with healthcare providers is crucial. Keep a symptom diary noting side effect severity, timing, and any triggers. This information helps clinicians determine whether effects are likely to resolve, require management strategies, or necessitate medication adjustment. Regular follow-up appointments allow monitoring of weight loss progress, side effects, and any necessary dose adjustments. If side effects significantly impair quality of life despite management strategies, alternative treatments should be discussed with your GP or specialist.

NHS-Approved Weight Loss Treatments and Their Safety Profiles

The NHS provides access to several evidence-based weight loss medications, each with established safety profiles and specific prescribing criteria aligned with NICE guidance.

Orlistat remains the most widely prescribed weight loss medication available through the NHS. NICE recommends orlistat for adults with a BMI of 28 kg/m² or above with associated risk factors (such as type 2 diabetes or hypertension), or a BMI of 30 kg/m² or above. Treatment should only continue beyond three months if the patient has lost at least 5% of initial body weight. Orlistat has an established safety record spanning over two decades, with gastrointestinal effects being the primary concern. Serious adverse events are rare, though isolated cases of severe liver injury have been reported, prompting recommendations for monitoring liver function if symptoms develop. Lower-dose orlistat (Alli 60 mg) is available from pharmacies without prescription for adults with a BMI of 28 kg/m² or above.

GLP-1 receptor agonists including semaglutide (Wegovy) and liraglutide (Saxenda) represent newer options with growing but variable NHS availability. Access depends on local commissioning decisions and specialist service capacity.

Semaglutide (Wegovy) is recommended by NICE (TA875) only within specialist weight management services (typically Tier 3 services) for a maximum of two years. It is usually offered to adults with an initial BMI of 35 kg/m² or above with at least one weight-related comorbidity, or in exceptional circumstances for those with a BMI of 30–34.9 kg/m² who meet specialist referral criteria. For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds, the BMI thresholds are reduced by 2.5 kg/m². Treatment should be stopped if the patient has not lost at least 5% of their initial body weight after six months.

Liraglutide (Saxenda) has more limited and variable NHS commissioning. Local eligibility criteria and availability should be confirmed with your GP or specialist service.

Both semaglutide and liraglutide require careful patient selection. Wegovy is contraindicated in pregnancy; women of childbearing potential should use effective contraception and stop semaglutide at least two months before a planned pregnancy. Saxenda should not be used during pregnancy. Regular monitoring includes assessment for pancreatitis symptoms, gallbladder disease, dehydration and kidney function, and, in people with diabetes, adjustment of other glucose-lowering medications to prevent hypoglycaemia and monitoring for diabetic retinopathy progression.

Naltrexone-bupropion (Mysimba) is not recommended by NICE and is not routinely available on the NHS. It may be prescribed privately in selected cases, but patients should be aware of contraindications including uncontrolled hypertension, seizure disorders, current or recent opioid use, and concurrent MAOI therapy, as well as the risk of neuropsychiatric side effects.

All NHS-prescribed weight loss medications should be part of a comprehensive programme including dietary modification, increased physical activity, and behavioural support, typically delivered through specialist weight management services. The MHRA and NHS continuously monitor safety data, and prescribing decisions should be individualised based on patient medical history, concurrent medications, and potential drug interactions. Patients should be informed that weight loss medications are not suitable for everyone, and lifestyle modification remains the foundation of effective, sustainable weight management.

Important: Only obtain weight loss medicines through registered UK pharmacies or NHS services. Do not purchase prescription medicines from unregulated online sources, as counterfeit and unlicensed products pose serious health risks. Report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Frequently Asked Questions